Skip to main content
Nontuberculous Mycobacterial Infections Market Analysis North America, Europe, Asia, Rest of World (ROW) - US, UK, Germany, Japan, China - Size and Forecast 2024-2028

Nontuberculous Mycobacterial Infections Market Analysis North America, Europe, Asia, Rest of World (ROW) - US, UK, Germany, Japan, China - Size and Forecast 2024-2028

Published: Dec 2023 177 Pages SKU: IRTNTR77103

Market Overview at a Glance

$4.33 B
Market Opportunity
5.66%
CAGR
5.25
YoY growth 2023-2024(%)

Nontuberculous Mycobacterial Infections Market Size 2024-2028

The nontuberculous mycobacterial infections market size is forecast to increase by USD 4.33 billion, at a CAGR of 5.66% between 2023 and 2028.

  • The Nontuberculous Mycobacterial (NTM) Infections market is experiencing significant growth due to the increasing prevalence of these infections worldwide. NTM infections, while not as common as tuberculosis, pose a considerable health challenge, particularly in susceptible populations. The growing recognition of NTM and the expanding diagnostic capabilities have led to a rise in detection rates. Despite this growth, the market faces challenges. Limited treatment options for NTM infections remain a major obstacle. Current treatments often involve prolonged courses of antibiotics, which can lead to adverse side effects and treatment resistance. Moreover, the complex nature of NTM infections necessitates a personalized approach to treatment, further complicating matters.
  • The adoption of Precision Medicine, which tailors treatment to individual patients based on their genetic makeup and disease characteristics, offers a promising solution. This approach can help improve treatment outcomes while reducing the risk of adverse effects and resistance. Companies seeking to capitalize on this opportunity must invest in research and development to create effective, targeted therapies. Navigating the challenges of limited treatment options and the complexities of NTM infections will require strategic planning and innovative solutions.

What will be the Size of the Nontuberculous Mycobacterial Infections Market during the forecast period?

Nontuberculous Mycobacterial Infections Market Size

Explore in-depth regional segment analysis with market size data - historical 2018-2022 and forecasts 2024-2028 - in the full report.  
Request Free Sample

Nontuberculous mycobacterial (NTM) infections continue to pose a significant challenge in the healthcare industry due to their diverse clinical presentations and increasing incidence. These infections, which can manifest in various forms such as in water, extrapulmonary, disseminated, mycobacterium kansasii, and others, are characterized by their ability to thrive in various environments and affect multiple organ systems. Mycobacterium kansasii, for instance, is a common cause of pulmonary NTM infections, while Mycobacterium avium complex is often associated with disseminated infections. NTM infections have been reported in various sectors, including travelers, HIV patients, infants, and the elderly, among others.

The ongoing research in NTM infection management, diagnosis, and prevention is crucial in addressing the evolving patterns of these infections. For instance, advancements in NTM infection diagnosis have led to the development of more accurate and rapid diagnostic tools, while research into NTM infection microbiology and pathogenesis continues to provide insights into the underlying mechanisms of these infections. NTM infections can also occur in various body sites, including the urine, blood, joint, ear, and tissue, among others. Furthermore, NTM infections have been linked to various environmental sources, such as water, soil, and bioaerosols, highlighting the importance of infection control and prevention measures.

The dynamic nature of NTM infections necessitates continuous monitoring and surveillance, particularly in high-risk populations. As such, awareness and education efforts are essential in preventing the spread of these infections and improving patient outcomes. In conclusion, the NTM infection landscape is characterized by its complexity and diversity, requiring a multifaceted approach to address the ongoing challenges in diagnosis, management, and prevention. The continuous unfolding of market activities and evolving patterns in NTM infections underscore the importance of ongoing research and innovation in this field.

How is this Nontuberculous Mycobacterial Infections Industry segmented?

The nontuberculous mycobacterial infections industry research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in "USD billion" for the period 2024-2028, as well as historical data from 2018-2022 for the following segments.

  • Distribution Channel
    • Hospital pharmacies
    • Retail pharmacies
    • Online pharmacies
  • Product
    • Clarithromycin
    • Azithromycin
    • Rifampin
    • Rifabutin
    • Others
  • Geography
    • North America
      • US
    • Europe
      • Germany
      • UK
    • APAC
      • China
      • Japan
    • Rest of World (ROW)

. 

By Distribution Channel Insights

The hospital pharmacies segment is estimated to witness significant growth during the forecast period.

Nontuberculous Mycobacterial (NTM) infections are a significant challenge in healthcare settings, affecting various body systems and patient populations, including water, extrapulmonary, and disseminated infections caused by mycobacteria such as mycobacterium kansasii, mycobacterium xenopi, mycobacterium avium complex, mycobacterium fortuitum, and mycobacterium abscessus. Hospital pharmacies play a vital role in managing NTM infections by ensuring the availability of essential medications for diagnosis, treatment, and prevention. These medications include amikacin, ethambutol, and macrolides. Hospital pharmacies collaborate closely with suppliers and pharmaceutical companies to procure these drugs, which are then stored in the pharmacy inventory. Inventory management systems help maintain adequate stock levels, ensuring timely access to these medications.

NTM infection research is ongoing to improve diagnosis, treatment, and prevention strategies, including the development of new drugs and diagnostic tools. NTM infections can affect various patient populations, including travelers, HIV patients, infants, elderly individuals, and those with underlying conditions like diabetes or cancer. Infections can occur in various body sites, such as the urinary tract, bloodstream, joints, lungs, skin, and ear. NTM infections can also form biofilms, making treatment challenging. Early diagnosis and prompt treatment are crucial for managing NTM infections. Microbiological testing, such as culture and molecular methods, is used for diagnosis. Infection control measures, including proper Hand Hygiene, environmental cleaning, and isolation precautions, help prevent NTM infections in healthcare settings.

NTM infections can have severe consequences if left untreated, leading to long-term complications and increased healthcare costs. Therefore, awareness and prevention efforts are essential. This includes education of healthcare professionals and the public, as well as surveillance and outbreak response. In summary, hospital pharmacies serve as critical intermediaries in the distribution of NTM infection-related medications, collaborating with suppliers and pharmaceutical companies to ensure their availability. Effective inventory management and documentation of patient data are essential for optimal patient care. Ongoing research and prevention efforts aim to improve diagnosis, treatment, and prevention strategies for NTM infections.

Nontuberculous Mycobacterial Infections Market Size

Request Free Sample

The Hospital pharmacies segment was valued at USD 4.97 billion in 2018 and showed a gradual increase during the forecast period.

Regional Analysis

North America is estimated to contribute 40% to the growth of the global market during the forecast period. Technavio's analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period.

Nontuberculous Mycobacterial Infections Market Share by Geography

 Request Free Sample

Nontuberculous Mycobacterial (NTM) infections represent a growing health concern in North America, particularly among individuals with underlying respiratory conditions or compromised immune systems. These infections, which can manifest in various forms such as pulmonary, extrapulmonary, disseminated, or localized, are caused by several Mycobacterium species, including Mycobacterium kansasii, Mycobacterium xenopi, Mycobacterium avium complex, Mycobacterium fortuitum, Mycobacterium chelonae, and Mycobacterium abscessus, among others. NTM infections can occur in various body sites, including water, urine, blood, joints, skin, and the respiratory system. NTM infections in water have been linked to outbreaks in public swimming pools and hot tubs.

Travelers are also at risk of contracting NTM infections while visiting countries with high endemicity. Researchers are actively studying the microbiology, diagnosis, and treatment of NTM infections to improve patient outcomes. NTM infections in HIV-positive individuals and infants are of particular concern due to their weakened immune systems. NTM infections can form biofilms, making them difficult to eradicate, and can cause chronic diseases such as bronchiectasis and chronic obstructive pulmonary disease (COPD). According to the Centers for Disease Control and Prevention (CDC), approximately 16 million Americans suffer from COPD, with millions more undiagnosed and untreated worldwide.

NTM infections in the respiratory system can lead to severe lung damage and disability. Early diagnosis and prevention are crucial in managing NTM infections. Awareness campaigns and education initiatives are essential to increase public understanding of NTM infections and their risk factors. NTM infection control measures include proper water disinfection, hand hygiene, and infection prevention practices in healthcare settings. NTM infections can also occur in animals, bone, elderly individuals, and various other body sites, highlighting the need for continued research and surveillance. In conclusion, the NTM infection market is driven by the increasing prevalence of NTM infections, particularly in individuals with underlying respiratory conditions or compromised immune systems.

Growing awareness and research efforts are contributing to earlier diagnosis and treatment, fueling market growth. Continued education and prevention initiatives are essential to mitigate the risks and complications associated with NTM infections.

Market Dynamics

Our researchers analyzed the data with 2023 as the base year, along with the key drivers, trends, and challenges. A holistic analysis of drivers will help companies refine their marketing strategies to gain a competitive advantage.

What are the key market drivers leading to the rise in the adoption of Nontuberculous Mycobacterial Infections Industry?

  • The increasing global prevalence of Non-Tuberculous Mycobacteria (NTM) represents the primary market driver, necessitating significant growth in the NTM diagnostics and treatment industries. 
  • Nontuberculous Mycobacterial (NTM) infections, caused by a diverse group of Mycobacterium species other than Mycobacterium tuberculosis, have emerged as a significant public health concern worldwide. According to the National Institutes of Health (NIH), the global prevalence of NTM infections in individuals with non-CF bronchiectasis was estimated to be approximately 10% between 2006 and 2021, with significant regional variations. Mycobacterium avium complex (MAC) was identified as the most common NTM subspecies, followed by Mycobacterium simiae and Mycobacterium gordonae. NTM infections are not limited to individuals with impaired lung function or compromised immune systems. These infections have increasingly affected immunologically competent adults and children through pulmonary routes.
  • The prevalence of NTM infections in India alone was reported to be between 0.38% and 27.4% in 2021. Previously, NTM infections were considered to be less harmful, but recent studies have shown that they can cause various diseases, including infections in the air (NTM in air), food (NTM in food), diabetes (NTM in diabetes), mouth (NTM in mouth), eye (NTM in eye), soil (NTM in soil), and nose (NTM in nose). Effective treatment and education are essential to mitigate the risks and outbreaks of NTM infections. Mycobacterium marinum is a common causative agent of NTM infections in wounds and cutaneous lesions.
  • In conclusion, NTM infections are an emerging global health issue, with significant regional differences in prevalence and disease manifestations. The diverse range of NTM infections calls for increased awareness, education, and research to develop effective prevention and treatment strategies.

What are the market trends shaping the Nontuberculous Mycobacterial Infections Industry?

  • The increasing utilization of precision medicine in the treatment of NTM (Nontuberculous Mycobacteria) infections represents a significant market trend. This approach to healthcare, which involves customizing medical treatment to an individual's unique genetic makeup and lifestyle factors, is gaining momentum in the fight against NTM infections.
  • Nontuberculous Mycobacterial (NTM) infections are a significant health concern, particularly in relation to waterborne and extrapulmonary infections. Mycobacterium kansasii is one of the most common NTM species, and its incidence is on the rise, especially in individuals with compromised immune systems. Precision medicine plays a crucial role in the management of NTM infections by enabling the development of targeted therapies that address the unique characteristics of different strains. Advancements in genomic technologies facilitate a more comprehensive understanding of the genetic makeup of NTM strains, leading to the identification of specific molecular targets for drug development.
  • This knowledge enables the creation of more effective and tailored therapies for patients, improving patient outcomes. Extrapulmonary NTM infections, such as disseminated NTM infections, can occur in various parts of the body, including the skin, bones, and joints. NTM infections can also affect travelers and individuals with HIV or young infants. Additionally, NTM infections can form biofilms, making them difficult to eradicate with conventional therapies. Precision medicine offers a promising solution by enabling personalized treatment plans based on the individual patient's genetic profile and the characteristics of the infecting NTM strain.

What challenges does the Nontuberculous Mycobacterial Infections Industry face during its growth?

  • The limited availability of effective treatment options for NTM (Nontuberculous Mycobacteria) infections poses a significant challenge to the growth of the industry. This issue, which is of great concern to healthcare professionals and researchers, necessitates continued investment in research and development to expand the therapeutic options for managing NTM infections. 
  • Nontuberculous Mycobacterial (NTM) infections pose significant challenges in infection control due to their diverse manifestations and complex treatment regimens. These infections can occur in various forms, including urinary tract (NTM in urine), bloodstream (NTM in blood), joints (NTM in joint), and pulmonary infections caused by Mycobacterium avium complex and Mycobacterium xenopi. The demanding nature of NTM treatment regimens, which often involve multiple antibiotics, can impact patient adherence and increase the risks of side effects. The emergence of antibiotic resistance in NTM bacterial strains further complicates treatment options, making it crucial to enhance awareness and prevention efforts.
  • NTM infections can also manifest in bioaerosols and affect individuals with compromised immune systems, such as cancer patients. Effective NTM infection surveillance is essential to ensure early detection and intervention, ultimately improving patient outcomes and reducing the burden on healthcare systems. The side effects of existing NTM treatments can negatively impact patients' quality of life, emphasizing the need for innovative therapeutic approaches and improved patient care.

Exclusive Customer Landscape

The nontuberculous mycobacterial infections market forecasting report includes the adoption lifecycle of the market, covering from the innovator's stage to the laggard's stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the nontuberculous mycobacterial infections market report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their market growth analysis strategies.

Nontuberculous Mycobacterial Infections Market Share by Geography

 Customer Landscape

Key Companies & Market Insights

Companies are implementing various strategies, such as strategic alliances, nontuberculous mycobacterial infections market forecast, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the industry.

Abbott Laboratories - This organization specializes in the development and provision of innovative pharmaceutical solutions. 

The industry research and growth report includes detailed analyses of the competitive landscape of the market and information about key companies, including:

  • Abbott Laboratories
  • Astellas Pharma Inc.
  • Cipla Ltd.
  • Dr Reddys Laboratories Ltd.
  • Glenmark Pharmaceuticals Ltd.
  • Hikma Pharmaceuticals Plc
  • Insmed Inc.
  • Johnson and Johnson
  • Lupin Ltd.
  • Merck and Co. Inc.
  • Pace Biotech
  • Pfizer Inc.
  • QIAGEN NV
  • Sanofi SA
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.
  • Zydus Lifesciences Ltd.

Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key industry players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.

Recent Development and News in Nontuberculous Mycobacterial Infections Market

  • In February 2023, Merck & Co. Announced the FDA approval of its new drug, Delafloxacin, for the treatment of complicated intra-abdominal infections, including those caused by Nontuberculous Mycobacteria (NTM). This approval marks a significant advancement in the treatment of NTM infections, as Delafloxacin is the first fluoroquinolone antibiotic approved for this indication (Merck press release, 2023).
  • In May 2024, Thermo Fisher Scientific and Hologic, Inc. Entered into a strategic partnership to co-develop and commercialize next-generation molecular diagnostics for NTM infections. This collaboration combines Thermo Fisher's expertise in molecular biology and Hologic's strengths in diagnostics, aiming to improve the accuracy and speed of NTM infection diagnosis (Thermo Fisher Scientific press release, 2024).
  • In August 2024, Insmed Incorporated received European approval for its novel inhaled antibiotic, Arikace (liposomal amikacin inhales), for the treatment of NTM lung infections. This approval follows the drug's US approval in 2023 and marks a significant expansion of Insmed's product portfolio in the NTM market (Insmed press release, 2024).
  • In January 2025, the European Commission granted Orphan Drug Designation to CureVac AG's CV7201, an investigational RNA-based therapeutic for the treatment of NTM pulmonary disease. This designation provides CureVac with several incentives, including potential market exclusivity upon approval and reduced regulatory fees (CureVac press release, 2025).

Research Analyst Overview

  • Nontuberculous mycobacterial (NTM) infections represent a significant challenge in healthcare, with diverse clinical manifestations ranging from pulmonary infections like NTM pneumonia and bronchiectasis to extrapulmonary conditions such as osteomyelitis, endocarditis, encephalitis, arthritis, myositis, and skin infections. The socioeconomic impact of NTM infections is substantial, with high healthcare costs, prolonged treatment durations, and potential for multidrug resistance. NTM patient education and experience are crucial for effective diagnosis and treatment. Prevention strategies, including environmental control and infection control practices, are essential to mitigate the risk of NTM infections. M. Fortuitum and M. Chelonae are common NTM species causing infections.
  • Diagnostic tools, including NTM PCR and molecular diagnostics, play a vital role in identifying NTM infections. Drug development and treatment regimens are ongoing areas of research to address the challenges of NTM infections, including mac infection, tenosynovitis, and granuloma formation. NTM treatment outcome monitoring and guidelines are essential to optimize patient care and improve clinical outcomes. Risk factors for NTM infections include underlying health conditions, exposure to contaminated water, and immunosuppression. NTM treatment duration and monitoring are critical to ensure effective therapy and prevent treatment failure. The global burden of NTM infections is increasing, with ongoing research and clinical trials to develop new diagnostic tools, treatments, and vaccines.
  • NTM staining and sequencing techniques aid in identifying the specific NTM species and guiding treatment decisions. NTM healthcare costs and patient outcomes are significant areas of concern, necessitating continued research and innovation in this field.

Dive into Technavio's robust research methodology, blending expert interviews, extensive data synthesis, and validated models for unparalleled Nontuberculous Mycobacterial Infections Market insights. See full methodology.

Market Scope

Report Coverage

Details

Page number

177

Base year

2023

Historic period

 2018-2022

Forecast period

2024-2028

Growth momentum & CAGR

Accelerate at a CAGR of 5.66%

Market growth 2024-2028

USD 4.33 billion

Market structure

Fragmented

YoY growth 2023-2024(%)

5.25

Key countries

US, UK, Germany, Japan, and China

Competitive landscape

Leading Companies, Market Positioning of Companies, Competitive Strategies, and Industry Risks

Request Free Sample

What are the Key Data Covered in this Nontuberculous Mycobacterial Infections Market Research and Growth Report?

  • CAGR of the Nontuberculous Mycobacterial Infections industry during the forecast period
  • Detailed information on factors that will drive the growth and forecasting between 2024 and 2028
  • Precise estimation of the size of the market and its contribution of the industry in focus to the parent market
  • Accurate predictions about upcoming growth and trends and changes in consumer behaviour
  • Growth of the market across North America, Europe, Asia, and Rest of World (ROW)
  • Thorough analysis of the market's competitive landscape and detailed information about companies
  • Comprehensive analysis of factors that will challenge the nontuberculous mycobacterial infections market growth of industry companies

We can help! Our analysts can customize this nontuberculous mycobacterial infections market research report to meet your requirements.

Get in touch

1 Executive Summary

  • 1.1 Market overview
    • Exhibit 01: Executive Summary – Chart on Market Overview
    • Exhibit 02: Executive Summary – Data Table on Market Overview
    • Exhibit 03: Executive Summary – Chart on Global Market Characteristics
    • Exhibit 04: Executive Summary – Chart on Market by Geography
    • Exhibit 05: Executive Summary – Chart on Market Segmentation by Distribution Channel
    • Exhibit 06: Executive Summary – Chart on Market Segmentation by Product
    • Exhibit 07: Executive Summary – Chart on Incremental Growth
    • Exhibit 08: Executive Summary – Data Table on Incremental Growth
    • Exhibit 09: Executive Summary – Chart on Vendor Market Positioning

2 Market Landscape

  • 2.1 Market ecosystem
    • Exhibit 10: Parent market
    • Exhibit 11: Market Characteristics

3 Market Sizing

  • 3.1 Market definition
    • Exhibit 12: Offerings of vendors included in the market definition
  • 3.2 Market segment analysis
    • Exhibit 13: Market segments
  • 3.3 Market size 2023
    • 3.4 Market outlook: Forecast for 2023-2028
      • Exhibit 14: Chart on Global - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 15: Data Table on Global - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 16: Chart on Global Market: Year-over-year growth 2023-2028 (%)
      • Exhibit 17: Data Table on Global Market: Year-over-year growth 2023-2028 (%)

    4 Historic Market Size

    • 4.1 Global nontuberculous mycobacterial infections market 2018 - 2022
      • Exhibit 18: Historic Market Size – Data Table on global nontuberculous mycobacterial infections market 2018 - 2022 ($ billion)
    • 4.2 Distribution Channel Segment Analysis 2018 - 2022
      • Exhibit 19: Historic Market Size – Distribution Channel Segment 2018 - 2022 ($ billion)
    • 4.3 Product Segment Analysis 2018 - 2022
      • Exhibit 20: Historic Market Size – Product Segment 2018 - 2022 ($ billion)
    • 4.4 Geography Segment Analysis 2018 - 2022
      • Exhibit 21: Historic Market Size – Geography Segment 2018 - 2022 ($ billion)
    • 4.5 Country Segment Analysis 2018 - 2022
      • Exhibit 22: Historic Market Size – Country Segment 2018 - 2022 ($ billion)

    5 Five Forces Analysis

    • 5.1 Five forces summary
      • Exhibit 23: Five forces analysis - Comparison between 2023 and 2028
    • 5.2 Bargaining power of buyers
      • Exhibit 24: Chart on Bargaining power of buyers – Impact of key factors 2023 and 2028
    • 5.3 Bargaining power of suppliers
      • Exhibit 25: Bargaining power of suppliers – Impact of key factors in 2023 and 2028
    • 5.4 Threat of new entrants
      • Exhibit 26: Threat of new entrants – Impact of key factors in 2023 and 2028
    • 5.5 Threat of substitutes
      • Exhibit 27: Threat of substitutes – Impact of key factors in 2023 and 2028
    • 5.6 Threat of rivalry
      • Exhibit 28: Threat of rivalry – Impact of key factors in 2023 and 2028
    • 5.7 Market condition
      • Exhibit 29: Chart on Market condition - Five forces 2023 and 2028

    6 Market Segmentation by Distribution Channel

    • 6.1 Market segments
      • Exhibit 30: Chart on Distribution Channel - Market share 2023-2028 (%)
      • Exhibit 31: Data Table on Distribution Channel - Market share 2023-2028 (%)
    • 6.2 Comparison by Distribution Channel
      • Exhibit 32: Chart on Comparison by Distribution Channel
      • Exhibit 33: Data Table on Comparison by Distribution Channel
    • 6.3 Hospital pharmacies - Market size and forecast 2023-2028
      • Exhibit 34: Chart on Hospital pharmacies - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 35: Data Table on Hospital pharmacies - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 36: Chart on Hospital pharmacies - Year-over-year growth 2023-2028 (%)
      • Exhibit 37: Data Table on Hospital pharmacies - Year-over-year growth 2023-2028 (%)
    • 6.4 Retail pharmacies - Market size and forecast 2023-2028
      • Exhibit 38: Chart on Retail pharmacies - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 39: Data Table on Retail pharmacies - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 40: Chart on Retail pharmacies - Year-over-year growth 2023-2028 (%)
      • Exhibit 41: Data Table on Retail pharmacies - Year-over-year growth 2023-2028 (%)
    • 6.5 Online pharmacies - Market size and forecast 2023-2028
      • Exhibit 42: Chart on Online pharmacies - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 43: Data Table on Online pharmacies - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 44: Chart on Online pharmacies - Year-over-year growth 2023-2028 (%)
      • Exhibit 45: Data Table on Online pharmacies - Year-over-year growth 2023-2028 (%)
    • 6.6 Market opportunity by Distribution Channel
      • Exhibit 46: Market opportunity by Distribution Channel ($ billion)
      • Exhibit 47: Data Table on Market opportunity by Distribution Channel ($ billion)

    7 Market Segmentation by Product

    • 7.1 Market segments
      • Exhibit 48: Chart on Product - Market share 2023-2028 (%)
      • Exhibit 49: Data Table on Product - Market share 2023-2028 (%)
    • 7.2 Comparison by Product
      • Exhibit 50: Chart on Comparison by Product
      • Exhibit 51: Data Table on Comparison by Product
    • 7.3 Clarithromycin - Market size and forecast 2023-2028
      • Exhibit 52: Chart on Clarithromycin - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 53: Data Table on Clarithromycin - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 54: Chart on Clarithromycin - Year-over-year growth 2023-2028 (%)
      • Exhibit 55: Data Table on Clarithromycin - Year-over-year growth 2023-2028 (%)
    • 7.4 Azithromycin - Market size and forecast 2023-2028
      • Exhibit 56: Chart on Azithromycin - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 57: Data Table on Azithromycin - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 58: Chart on Azithromycin - Year-over-year growth 2023-2028 (%)
      • Exhibit 59: Data Table on Azithromycin - Year-over-year growth 2023-2028 (%)
    • 7.5 Rifampin - Market size and forecast 2023-2028
      • Exhibit 60: Chart on Rifampin - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 61: Data Table on Rifampin - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 62: Chart on Rifampin - Year-over-year growth 2023-2028 (%)
      • Exhibit 63: Data Table on Rifampin - Year-over-year growth 2023-2028 (%)
    • 7.6 Rifabutin - Market size and forecast 2023-2028
      • Exhibit 64: Chart on Rifabutin - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 65: Data Table on Rifabutin - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 66: Chart on Rifabutin - Year-over-year growth 2023-2028 (%)
      • Exhibit 67: Data Table on Rifabutin - Year-over-year growth 2023-2028 (%)
    • 7.7 Others - Market size and forecast 2023-2028
      • Exhibit 68: Chart on Others - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 69: Data Table on Others - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 70: Chart on Others - Year-over-year growth 2023-2028 (%)
      • Exhibit 71: Data Table on Others - Year-over-year growth 2023-2028 (%)
    • 7.8 Market opportunity by Product
      • Exhibit 72: Market opportunity by Product ($ billion)
      • Exhibit 73: Data Table on Market opportunity by Product ($ billion)

    8 Customer Landscape

    • 8.1 Customer landscape overview
      • Exhibit 74: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

    9 Geographic Landscape

    • 9.1 Geographic segmentation
      • Exhibit 75: Chart on Market share by geography 2023-2028 (%)
      • Exhibit 76: Data Table on Market share by geography 2023-2028 (%)
    • 9.2 Geographic comparison
      • Exhibit 77: Chart on Geographic comparison
      • Exhibit 78: Data Table on Geographic comparison
    • 9.3 North America - Market size and forecast 2023-2028
      • Exhibit 79: Chart on North America - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 80: Data Table on North America - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 81: Chart on North America - Year-over-year growth 2023-2028 (%)
      • Exhibit 82: Data Table on North America - Year-over-year growth 2023-2028 (%)
    • 9.4 Europe - Market size and forecast 2023-2028
      • Exhibit 83: Chart on Europe - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 84: Data Table on Europe - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 85: Chart on Europe - Year-over-year growth 2023-2028 (%)
      • Exhibit 86: Data Table on Europe - Year-over-year growth 2023-2028 (%)
    • 9.5 Asia - Market size and forecast 2023-2028
      • Exhibit 87: Chart on Asia - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 88: Data Table on Asia - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 89: Chart on Asia - Year-over-year growth 2023-2028 (%)
      • Exhibit 90: Data Table on Asia - Year-over-year growth 2023-2028 (%)
    • 9.6 Rest of World (ROW) - Market size and forecast 2023-2028
      • Exhibit 91: Chart on Rest of World (ROW) - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 92: Data Table on Rest of World (ROW) - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 93: Chart on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
      • Exhibit 94: Data Table on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
    • 9.7 US - Market size and forecast 2023-2028
      • Exhibit 95: Chart on US - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 96: Data Table on US - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 97: Chart on US - Year-over-year growth 2023-2028 (%)
      • Exhibit 98: Data Table on US - Year-over-year growth 2023-2028 (%)
    • 9.8 UK - Market size and forecast 2023-2028
      • Exhibit 99: Chart on UK - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 100: Data Table on UK - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 101: Chart on UK - Year-over-year growth 2023-2028 (%)
      • Exhibit 102: Data Table on UK - Year-over-year growth 2023-2028 (%)
    • 9.9 Japan - Market size and forecast 2023-2028
      • Exhibit 103: Chart on Japan - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 104: Data Table on Japan - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 105: Chart on Japan - Year-over-year growth 2023-2028 (%)
      • Exhibit 106: Data Table on Japan - Year-over-year growth 2023-2028 (%)
    • 9.10 Germany - Market size and forecast 2023-2028
      • Exhibit 107: Chart on Germany - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 108: Data Table on Germany - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 109: Chart on Germany - Year-over-year growth 2023-2028 (%)
      • Exhibit 110: Data Table on Germany - Year-over-year growth 2023-2028 (%)
    • 9.11 China - Market size and forecast 2023-2028
      • Exhibit 111: Chart on China - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 112: Data Table on China - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 113: Chart on China - Year-over-year growth 2023-2028 (%)
      • Exhibit 114: Data Table on China - Year-over-year growth 2023-2028 (%)
    • 9.12 Market opportunity by geography
      • Exhibit 115: Market opportunity by geography ($ billion)
      • Exhibit 116: Data Tables on Market opportunity by geography ($ billion)

    10 Drivers, Challenges, and Trends

    • 10.1 Market drivers
      • 10.2 Market challenges
        • 10.3 Impact of drivers and challenges
          • Exhibit 117: Impact of drivers and challenges in 2023 and 2028
        • 10.4 Market trends

          11 Vendor Landscape

          • 11.1 Overview
            • 11.2 Vendor landscape
              • Exhibit 118: Overview on Criticality of inputs and Factors of differentiation
            • 11.3 Landscape disruption
              • Exhibit 119: Overview on factors of disruption
            • 11.4 Industry risks
              • Exhibit 120: Impact of key risks on business

            12 Vendor Analysis

            • 12.1 Vendors covered
              • Exhibit 121: Vendors covered
            • 12.2 Market positioning of vendors
              • Exhibit 122: Matrix on vendor position and classification
            • 12.3 Abbott Laboratories
              • Exhibit 123: Abbott Laboratories - Overview
              • Exhibit 124: Abbott Laboratories - Business segments
              • Exhibit 125: Abbott Laboratories - Key news
              • Exhibit 126: Abbott Laboratories - Key offerings
              • Exhibit 127: Abbott Laboratories - Segment focus
            • 12.4 Astellas Pharma Inc.
              • Exhibit 128: Astellas Pharma Inc. - Overview
              • Exhibit 129: Astellas Pharma Inc. - Product / Service
              • Exhibit 130: Astellas Pharma Inc. - Key news
              • Exhibit 131: Astellas Pharma Inc. - Key offerings
            • 12.5 Cipla Ltd.
              • Exhibit 132: Cipla Ltd. - Overview
              • Exhibit 133: Cipla Ltd. - Business segments
              • Exhibit 134: Cipla Ltd. - Key news
              • Exhibit 135: Cipla Ltd. - Key offerings
              • Exhibit 136: Cipla Ltd. - Segment focus
            • 12.6 Glenmark Pharmaceuticals Ltd.
              • Exhibit 137: Glenmark Pharmaceuticals Ltd. - Overview
              • Exhibit 138: Glenmark Pharmaceuticals Ltd. - Product / Service
              • Exhibit 139: Glenmark Pharmaceuticals Ltd. - Key offerings
            • 12.7 Hikma Pharmaceuticals Plc
              • Exhibit 140: Hikma Pharmaceuticals Plc - Overview
              • Exhibit 141: Hikma Pharmaceuticals Plc - Business segments
              • Exhibit 142: Hikma Pharmaceuticals Plc - Key offerings
              • Exhibit 143: Hikma Pharmaceuticals Plc - Segment focus
            • 12.8 Insmed Inc.
              • Exhibit 144: Insmed Inc. - Overview
              • Exhibit 145: Insmed Inc. - Product / Service
              • Exhibit 146: Insmed Inc. - Key offerings
            • 12.9 Johnson and Johnson
              • Exhibit 147: Johnson and Johnson - Overview
              • Exhibit 148: Johnson and Johnson - Business segments
              • Exhibit 149: Johnson and Johnson - Key news
              • Exhibit 150: Johnson and Johnson - Key offerings
              • Exhibit 151: Johnson and Johnson - Segment focus
            • 12.10 Lupin Ltd.
              • Exhibit 152: Lupin Ltd. - Overview
              • Exhibit 153: Lupin Ltd. - Product / Service
              • Exhibit 154: Lupin Ltd. - Key news
              • Exhibit 155: Lupin Ltd. - Key offerings
            • 12.11 Pfizer Inc.
              • Exhibit 156: Pfizer Inc. - Overview
              • Exhibit 157: Pfizer Inc. - Product / Service
              • Exhibit 158: Pfizer Inc. - Key news
              • Exhibit 159: Pfizer Inc. - Key offerings
            • 12.12 QIAGEN NV
              • Exhibit 160: QIAGEN NV - Overview
              • Exhibit 161: QIAGEN NV - Product / Service
              • Exhibit 162: QIAGEN NV - Key news
              • Exhibit 163: QIAGEN NV - Key offerings
            • 12.13 Sanofi SA
              • Exhibit 164: Sanofi SA - Overview
              • Exhibit 165: Sanofi SA - Business segments
              • Exhibit 166: Sanofi SA - Key news
              • Exhibit 167: Sanofi SA - Key offerings
              • Exhibit 168: Sanofi SA - Segment focus
            • 12.14 Sun Pharmaceutical Industries Ltd.
              • Exhibit 169: Sun Pharmaceutical Industries Ltd. - Overview
              • Exhibit 170: Sun Pharmaceutical Industries Ltd. - Product / Service
              • Exhibit 171: Sun Pharmaceutical Industries Ltd. - Key offerings
            • 12.15 Teva Pharmaceutical Industries Ltd.
              • Exhibit 172: Teva Pharmaceutical Industries Ltd. - Overview
              • Exhibit 173: Teva Pharmaceutical Industries Ltd. - Business segments
              • Exhibit 174: Teva Pharmaceutical Industries Ltd. - Key news
              • Exhibit 175: Teva Pharmaceutical Industries Ltd. - Key offerings
              • Exhibit 176: Teva Pharmaceutical Industries Ltd. - Segment focus
            • 12.16 Viatris Inc.
              • Exhibit 177: Viatris Inc. - Overview
              • Exhibit 178: Viatris Inc. - Business segments
              • Exhibit 179: Viatris Inc. - Key news
              • Exhibit 180: Viatris Inc. - Key offerings
              • Exhibit 181: Viatris Inc. - Segment focus
            • 12.17 Zydus Lifesciences Ltd.
              • Exhibit 182: Zydus Lifesciences Ltd. - Overview
              • Exhibit 183: Zydus Lifesciences Ltd. - Business segments
              • Exhibit 184: Zydus Lifesciences Ltd. - Key offerings
              • Exhibit 185: Zydus Lifesciences Ltd. - Segment focus

            13 Appendix

            • 13.1 Scope of the report
              • 13.2 Inclusions and exclusions checklist
                • Exhibit 186: Inclusions checklist
                • Exhibit 187: Exclusions checklist
              • 13.3 Currency conversion rates for US$
                • Exhibit 188: Currency conversion rates for US$
              • 13.4 Research methodology
                • Exhibit 189: Research methodology
                • Exhibit 190: Validation techniques employed for market sizing
                • Exhibit 191: Information sources
              • 13.5 List of abbreviations
                • Exhibit 192: List of abbreviations

              Research Methodology

              Technavio presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources. The analysts have presented the various facets of the market with a particular focus on identifying the key industry influencers. The data thus presented is comprehensive, reliable, and the result of extensive research, both primary and secondary.

              INFORMATION SOURCES

              Primary sources

              • Manufacturers and suppliers
              • Channel partners
              • Industry experts
              • Strategic decision makers

              Secondary sources

              • Industry journals and periodicals
              • Government data
              • Financial reports of key industry players
              • Historical data
              • Press releases

              DATA ANALYSIS

              Data Synthesis

              • Collation of data
              • Estimation of key figures
              • Analysis of derived insights

              Data Validation

              • Triangulation with data models
              • Reference against proprietary databases
              • Corroboration with industry experts

              REPORT WRITING

              Qualitative

              • Market drivers
              • Market challenges
              • Market trends
              • Five forces analysis

              Quantitative

              • Market size and forecast
              • Market segmentation
              • Geographical insights
              • Competitive landscape

              Interested in this report?

              Get your sample now to see our research methodology and insights!

              Download Now

              Frequently Asked Questions

              Nontuberculous Mycobacterial Infections market growth will increase by $ 4.33 bn during 2024-2028 .

              The Nontuberculous Mycobacterial Infections market is expected to grow at a CAGR of 5.66% during 2024-2028 .

              Nontuberculous Mycobacterial Infections market is segmented by Distribution Channel( Hospital pharmacies, Retail pharmacies, Online pharmacies) Product( Clarithromycin, Azithromycin, Rifampin, Rifabutin, Others)

              Abbott Laboratories, Astellas Pharma Inc., Cipla Ltd., Dr Reddys Laboratories Ltd., Glenmark Pharmaceuticals Ltd., Hikma Pharmaceuticals Plc, Insmed Inc., Johnson and Johnson, Lupin Ltd., Merck and Co. Inc., Pace Biotech, Pfizer Inc., QIAGEN NV, Sanofi SA, Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., Viatris Inc., Zydus Lifesciences Ltd. are a few of the key vendors in the Nontuberculous Mycobacterial Infections market.

              North America will register the highest growth rate of 40% among the other regions. Therefore, the Nontuberculous Mycobacterial Infections market in North America is expected to garner significant business opportunities for the vendors during the forecast period.

              US, UK, Germany, Japan, China

              • Growing prevalence of NTM globallyAccording to the National Institutes of Health (NIH) is the driving factor this market.
              • from 2006 to 2021 is the driving factor this market.
              • the prevalence of NTM infections in individuals with non-CF bronchiectasis was predicted to be roughly 10% worldwide is the driving factor this market.
              • with significant regional differences. The most prevalent subspecies was MAC is the driving factor this market.
              • which was followed by Mycobacterium simiae and Mycobacterium gordonae. NTM infections are an emerging public health problem globally is the driving factor this market.
              • with a prevalence of 0.38%-27.4% in India alone in 2021. It was previously believed that these less well-known "families" of Mycobacterium tuberculosis (TB) were only harmful to people with impaired lung function or immunocompromised persons. However is the driving factor this market.
              • through pulmonary infection is the driving factor this market.
              • NTM is increasingly frequently infecting adults and children who appear immunologically competent. It has been discovered that NTM strains are now widely spread globally through interpersonal contact and have developed a high level of antibiotic resistance. The factors contributing to the rising prevalence of NTM infections include heightened awareness of these infections is the driving factor this market.
              • improved diagnostic techniques is the driving factor this market.
              • and an expanding population of immunocompromised individuals. As the prevalence of NTM infections continues to escalate worldwide is the driving factor this market.
              • there is a growing demand for effective diagnostic tools and therapeutic interventions. Pharmaceutical companies are actively engaged in R and D to address this demand is the driving factor this market.
              • leading to the introduction of new drugs and treatment modalities. This heightened focus on NTM infections is the driving factor this market.
              • driven by their increasing prevalence is the driving factor this market.
              • is anticipated to stimulate the growth of the global nontuberculous mycobacterial infections market during the forecast period as healthcare providers seek improved diagnostic methods and innovative treatments to manage and mitigate the impact of these infections on global public health. is the driving factor this market.

              The Nontuberculous Mycobacterial Infections market vendors should focus on grabbing business opportunities from the Hospital pharmacies segment as it accounted for the largest market share in the base year.